Suresh K Rayala
Suresh K Rayala is an expert in Biochemistry at Indian Institute of Technology Madras (India). As of August 2026, ScienceLeadR ranks Suresh K Rayala in the top 1% of experts in India for Breast Neoplasms and Breast Diseases. Suresh K Rayala has authored 116 publications, the most recent in 2026. SLR score: 375 (community average: 125). How the SLR is computed.
LeadR Profile
Biochemistry
Subspecialties: Oncology - Hematology - Gastroenterology
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 2005 - 2026
Number : 116
Citations
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| PELP1 expression is associated with disease progression in inflammation-driven oral cancer. PMID 42604464 — cells, neoplasms, disease progression, tissues, mucous membrane, mouth neoplasms | Clin Transl Oncol | 2026 | 0 |
| Emerging biomarkers in breast fibroadenoma: implications for differential diagnosis, malignant transformation, and precision medicine. PMID 42530698 — diagnosis, differential, breast neoplasms, molecular biology, pathology, biomarkers, breast, precision medicine, diagnosis, fibroadenoma, wounds and injuries, prognosis | Mol Biol Rep | 2026 | 0 |
| AMPK/mTORC2/AKT-473/RUNX2 signaling axis modulates epithelial-mesenchymal transition and bone tropism in breast cancer. PMID 42038368 — tropism, cells, breast neoplasms, epithelial-mesenchymal transition, neoplasms, mechanistic target of rapamycin complex 2, neoplasm metastasis, breast, therapeutics, metformin | Front Oncol | 2026 | 0 |
| Sugars to signals: emerging roles of PAK1 in Re-wiring glucose metabolism in cancers. PMID 41437263 — cells, neoplasms, sugars, drug delivery systems, therapeutics, protein serine-threonine kinases | Expert Opin Ther Targets | 2025 | 0 |
| Expression of Transmembrane Glycoprotein TROP2 in Triple-Negative Breast Cancer and It's Potential as a Molecular Classifier for Targeted Therapy. PMID 41403267 — cells, triple negative breast neoplasms, breast neoplasms, antigens, surface, neoplasms, glycoproteins, breast, therapeutics, medical oncology | Cancer Invest | 2025 | 0 |
LeadR Networks
Main global connection map